We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





End-to-End Diagnostic Platform Could Be Game Changer for En-Masse, Rapid and Precise COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 27 Oct 2021

A new diagnostic platform could be a game-changing, end-to-end solution for en-masse, rapid and precise diagnosis of COVID-19 and other viruses at the point-of-care (POC). More...

Dotz Nano Ltd.’s (Kefar-Sava, Israel) Mega-Diagnostic Platform is an all-in-one solution that consists of proprietary DOTZ Test Kits, an integrated diagnostic system, and a results-management system. The Dotz Mega-Diagnostic Platform is based on RT-LAMP (Loop-Mediated Isothermal Amplification) technology with >95% true positive rate for viral loads of 1250 copies per mL; and 100% specificity.

Dotz’s platform provides an integrated and cost-efficient solution for SARS-CoV-2 testing that has the capacity to simultaneously test up to 96 samples per device in approximately 30 minutes. The test produces a visually-detectable change in the color of samples, ensuring a simple and rapid analysis procedure. The platform can use both saliva and nasopharyngeal samples for a more comfortable testing experience, particularly for children.

The Dotz Mega-Diagnostic Platform can be used in organizations or locations that are required to perform large numbers of tests in a short time, such as airports, universities, factories, workplaces, border crossings, and more. It requires minimal operator training, thereby significantly lowering overhead costs such as medical personnel and laboratory equipment. Dotz’s diagnostic solution has been granted CE Mark Authorization from the European Union, and it has also applied for Emergency Use Authorization from the FDA. Dotz will showcase its Mega-Diagnostic Platform for the first time at the MEDICA 2021 Trade Fair in Dusseldorf, Germany, November 15-18th.

“From the outbreak of the pandemic up to this point, en-masse and accurate detection of COVID-19 relied on complex and slow methods that must be performed in well-equipped laboratories by trained personnel,” said Gideon Shmuel, CEO of Dotz. “Our integrated, simple-to-use solution brings rapid and highly-accurate testing capabilities to the field, supporting a resumption of normal economic activity while keeping those transiting highly-trafficked public spaces healthy and safe.”

Related Links:
Dotz Nano Ltd. 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.